Company News

Kelun-Biotech will present the results from two clinical studies of SKB264/sac-TMT at the 2024 AACR Annual Meeting.

KLUS Pharma will attend the annual BIO-Europe Spring conference in Barcelona from March 18-20, 2024.

KLUS Pharma will attend the 14th World ADC conference in London from March 12-15, 2024.

KLUS Pharma will attend the AACR Annual Meeting in San Diego, CA from April 5-10, 2024.

Kelun-Biotech presented updated clinical results of SKB264 (MK-2870) in TNBC at 2023 SABCS.

A400/EP0031 is granted Orphan Drug designation by FDA for RET-fusion positive cancers

Selected for mini-oral presentation at 2023 ESMO: Kelun-Biotech to announce latest clinical study results of SKB264 (MK-2870, TROP2-ADC)

Kelun-Biotech officially debuts with HK$13.58 billion IPO on HKEX

CTA of Kelun-Biotech's TROP2-ADC (SKB264, MK-2870) in combination with pembrolizumab is approved in the European Union.

Kelun-Biotech will present results of Phase 2 study of SKB264 (TROP2 ADC) in metastatic NSCLC.

KLUS Pharma is attending 2023 ASCO Annual Meeting in Chicago from June 2-6th

KLUS Pharma will attend the BIO International Convention in Boston, MA from June 5-8, 2023.